Acute Myeloid Leukemia ICD-10 Code: Pharmaceutical Adverse Effect Coding Reference

Legacy of Health Information and Transition to Risk Context

Public health information systems have historically provided accessible, general knowledge about disease states and their physiological underpinnings. This heritage emphasized broad awareness—explaining what a condition is, how it manifests, and the basic anatomical context. As this informational landscape evolved, the focus shifted from purely descriptive disease education toward a more applied, risk-oriented perspective. This progression moves beyond the question of *what* a disease is to the more pressing question of *why* it develops in specific populations. This pivot necessitates a transition from general health literacy into the specialized domain of occupational and environmental health, where the concern is not solely about pathology itself but about antecedent conditions that elevate risk. This is particularly relevant when considering exposures encountered in professional duties, where the identification of a specific diagnostic code, such as that for a hematological malignancy, serves as a critical endpoint for surveillance.

Clinical Presentation and Diagnosis of Adverse Health Effects

Adverse health effects associated with pharmaceutical exposure encompass a broad spectrum of clinical presentations, ranging from acute hypersensitivity reactions to delayed oncologic complications. In the context of hematologic malignancies, the clinical presentation of treatment-related acute myeloid leukemia (AML) typically includes symptoms attributable to bone marrow failure: fatigue, pallor, dyspnea on exertion, recurrent infections, and bleeding manifestations such as petechiae or ecchymoses. Extramedullary involvement may present as gingival hypertrophy, skin nodules, or lymphadenopathy. Diagnosis requires a complete blood count with peripheral blood smear, bone marrow aspiration and biopsy, flow cytometry for immunophenotyping, and cytogenetic/molecular genetic analysis to identify recurrent chromosomal abnormalities (e.g., t(8;21), inv(16), t(15;17), 11q23 rearrangements) and gene mutations (e.g., NPM1, FLT3, CEBPA, TP53). The diagnostic workup must also exclude other causes of cytopenias and confirm the clonal nature of the myeloid blast population, with a blast threshold of ≥20% in bone marrow or peripheral blood, unless specific recurrent genetic abnormalities are present.

Pharmaceutical Pharmacology and Reported Adverse Effects

Pharmaceutical agents implicated in therapy-related AML include alkylating agents (e.g., cyclophosphamide, melphalan, busulfan), topoisomerase II inhibitors (e.g., etoposide, doxorubicin), and antimetabolites (e.g., azathioprine, mercaptopurine). Alkylating agents induce DNA cross-links and strand breaks, leading to chromosomal deletions and loss of tumor suppressor function. Therapy-related AML following alkylating agent exposure typically presents 5–10 years after treatment, often with preceding myelodysplastic syndrome and characteristic cytogenetic abnormalities involving chromosomes 5 and 7 (e.g., del(5q), monosomy 7). Topoisomerase II inhibitors cause DNA double-strand breaks by stabilizing the enzyme-DNA cleavage complex, resulting in balanced chromosomal translocations, particularly involving the MLL gene at 11q23. This form of therapy-related AML has a shorter latency period of 1–3 years and often presents without a preceding myelodysplastic phase. Antimetabolites interfere with DNA synthesis and repair, and their association with secondary leukemias is less well-defined but has been reported in patients receiving prolonged immunosuppressive therapy.

Mechanistic Pathways Linking Pharmaceutical Exposure to Adverse Health Effect

The mechanistic pathways linking pharmaceutical exposure to the development of AML involve direct DNA damage, impaired DNA repair mechanisms, and clonal selection of hematopoietic stem or progenitor cells. Alkylating agents produce DNA adducts that, if unrepaired, lead to mutations and chromosomal aberrations. Defects in the nucleotide excision repair or homologous recombination pathways increase susceptibility to these genotoxic effects. Topoisomerase II inhibitors induce site-specific DNA cleavage, and the resulting translocations can activate proto-oncogenes or create fusion genes that disrupt normal hematopoietic differentiation. Additionally, pharmaceutical-induced oxidative stress and chronic inflammation may contribute to genomic instability. The bone marrow microenvironment, including stromal cells and cytokines, may also play a role in promoting the survival and proliferation of preleukemic clones. Individual genetic polymorphisms in drug-metabolizing enzymes (e.g., cytochrome P450 variants) and DNA repair genes (e.g., GSTT1, XRCC1) can modulate the risk of therapy-related AML, explaining interpatient variability in susceptibility.

Safety-Communication Context Regarding Pharmaceutical and Adverse Health Effect

Regulatory safety communications and product labeling for pharmaceuticals associated with therapy-related AML emphasize the need for careful risk-benefit assessment prior to initiation of therapy. Prescribing information includes warnings about the potential for secondary malignancies, particularly in patients receiving prolonged or high-dose regimens, those with prior exposure to cytotoxic agents, or those with underlying genetic predisposition. Healthcare professionals are advised to monitor patients for signs of hematologic toxicity, including persistent cytopenias, and to perform appropriate diagnostic evaluations if AML is suspected. Patients should be counseled about the signs and symptoms of leukemia and the importance of regular follow-up blood counts. The risk of therapy-related AML is generally low but is dose-dependent and cumulative; therefore, treatment protocols should minimize unnecessary exposure to known leukemogenic agents, especially in younger patients with curable primary malignancies. Post-marketing surveillance and long-term follow-up studies contribute to the ongoing characterization of this adverse effect.

CodingReference-Focused Clinical Interpretation for Affected Patients

For affected patients, the accurate coding of therapy-related AML is essential for clinical documentation, treatment planning, and epidemiological tracking. The ICD-10-CM code for acute myeloid leukemia is C92.0 (Acute myeloblastic leukemia). However, when the leukemia is attributable to a pharmaceutical agent, the external cause code should be assigned to indicate the adverse effect of the drug. The appropriate code for adverse effects of drugs, medicaments, and biological substances in therapeutic use is T36–T50, with the specific drug category selected based on the pharmaceutical agent involved. For example, adverse effects of antineoplastic agents are coded under T45.1X5 (Adverse effect of antineoplastic and immunosuppressive drugs). The sequencing of codes requires the manifestation (C92.0) to be listed first, followed by the external cause code (T45.1X5) to indicate the drug-induced etiology. Additionally, if the patient has a history of a primary malignancy for which the pharmaceutical was administered, the personal history code (e.g., Z85.3 for malignant neoplasm of breast) may be reported as an additional diagnosis. For pathology and gene coding, the WHO classification of myeloid neoplasms should be referenced, and specific genetic abnormalities should be documented using appropriate molecular pathology codes (e.g., CPT codes for cytogenetic and molecular genetic testing). The timeline between pharmaceutical exposure and the documented health outcome is critical for establishing causality; therapy-related AML typically occurs months to years after exposure, and this temporal relationship should be clearly documented in the medical record to support the coding and clinical interpretation.

Timeline Between Exposure and Documented Health Outcomes

The latency period between pharmaceutical exposure and the development of therapy-related AML varies according to the class of drug. Alkylating agent-related AML has a median latency of 5–7 years, with a peak incidence between 5 and 10 years post-exposure. Topoisomerase II inhibitor-related AML has a shorter latency, typically 1–3 years. The risk is highest in patients who receive combination chemotherapy, radiation therapy, or autologous stem cell transplantation. The cumulative dose and the intensity of the treatment regimen are important determinants of risk. Patients who develop therapy-related AML generally have a poorer prognosis compared to de novo AML, due to higher rates of adverse cytogenetic abnormalities and resistance to conventional chemotherapy. Therefore, early recognition and accurate coding are essential for appropriate clinical management and for the ongoing assessment of pharmaceutical safety.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

ICD-10-CM reference — C92.0

Field	Value
ICD-10-CM Code	C92.0
Descriptor	Acute myeloblastic leukemia
Billable	Yes
Includes	Acute myeloid leukemia, AML, acute non-lymphocytic leukemia
Excludes1	Acute promyelocytic leukemia (C92.4)
Excludes2	Myelodysplastic syndrome (D46)
Adverse effect code	T45.1X5 (antineoplastic and immunosuppressive drugs)
Personal history code	Z85.3 (malignant neoplasm of breast) if applicable
Coding guideline	Manifestation code first, then external cause code

Frequently Asked Questions

What is the ICD-10-CM code for acute myeloid leukemia?

The ICD-10-CM code for acute myeloid leukemia is C92.0 (Acute myeloblastic leukemia). This code is used to indicate the diagnosis of AML, and when the leukemia is therapy-related, an additional external cause code from T36-T50 is assigned to specify the drug-induced etiology.

How is therapy-related AML coded in ICD-10-CM?

Therapy-related AML is coded by listing the manifestation code C92.0 first, followed by the external cause code for the adverse effect of the drug. For example, T45.1X5 (Adverse effect of antineoplastic and immunosuppressive drugs) is used for antineoplastic agents. Additional codes for personal history of primary malignancy may be reported if applicable.

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

References

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.